跳至主要内容
临床试验/JPRN-jRCTs031210393
JPRN-jRCTs031210393招募中3 期

JCOG2002: A randomized phase III study of thoracic radiotherapy for extensive stage small cell lung cancer - yES-TRT study

IHO Seiji0 个研究点目标入组 330 人开始时间: 2021年10月27日最近更新:

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
330

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • Primary registration criteria
  • (1) Cytologically or histologically confirmed small cell lung cancer. class IV or class V was required for cytology.
  • (2) Extensive stage was diagnosed by thoracoabdominal contrast-enhanced CT, FDG-PETand brain contrast-enhanced MRI.Lymph node metastasis exists either the supraclavicular/mediastinal lymph node or the ipsilateral hilar lymph node.
  • (3) Over 20 years old.
  • (4) Performance status 0, 1 or 2.
  • (5) Measureable or non-measureable.
  • (6) No history of radiation therapy or chemotherapy for small cell lung cancer.
  • (i) No prior palliative radiation therapy for non-central nervous system metastases within 7 days
  • (ii) No prior stereotactic irradiation for central nervous system metastases within 7 days
  • (iii) No prior whole-brain irradiation within 14 days
  • (7) No history of radiation therapy with supraclavicular, mediastinal, or hilar for other cancer types.
  • (8) Major organ function is preserved.
  • (i) Neutrophil count >= 1,500 /mm3
  • (ii) Hemoglobin >= 9.0 mg/dl
  • (iii) Platelet count >= 100,000 /mm3
  • (iv) T-bil <=1.5 mg/dL
  • (v) AST =< 100 U/L (=< 200 U/L in case of liver metastases)
  • (vi) ALT =< 100 U/L (=< 200 U/L in case of liver metastases)
  • (vii) Serum creatinine <=1.5 mg/dL
  • (viii) SpO2 >= 92%
  • (9) No active autoimmune disease.
  • (10) No serious tumor-related complications.
  • (11) Written informed consent.
  • Secondary registration selection criteria
  • (1) Primary registration was performed. Four course of ACE therapy or DPE therapy was completed, or only three course of ACE therapy or DPE therapy is completed due to adverse events.
  • (2) Following (i)-(iii) is satisfied.
  • (i) Contrast-enhanced CT after 2 courses of induction therapy does not show obvious progressions compared to CT before primary registration.
  • (ii) Contrast-enhanced CT after 4 courses of induction therapy does not show obvious progressions compared to CT after 2 courses of induction therapy.
  • (iii) No obvious progressions from the start of induction therapy.
  • (3) Within 7-42 days from the start of the final course of induction therapy.
  • (4) Within 64-182 days from the primary registration.
  • (5) Performance status 0 or 1.
  • (6) Judged that radiation therapy for the hilum and mediastinum was possible by consulting with a radiologist.
  • (7) Major organ function is preserved.
  • (i) Neutrophil count >= 1,500 /mm3
  • (ii) Hemoglobin >= 9.0 mg/dl
  • (iii) Platelet count >= 100,000 /mm3
  • (iv) T-bil <=1.5 mg/dL
  • (v) AST =< 100 U/L (=< 200 U/L in case of liver metastases)
  • (vi) ALT =< 100 U/L (=< 200 U/L in case of liver metastases)
  • (vii) Serum creatinine <=1.5 mg/dL
  • (viii) SpO2 >= 92%
  • (8) No drug-induced interstitial pneumonia or pulmonary fibrosis diagnosed by chest CT.
  • (9) No tracheoesophageal fistula, bronchoesophageal fistula, tracheal mediastinal fistula, or bronchial mediastinal fistula.

排除标准

  • (1) Simultaneous or metachronous (within 2 years) double cancers , with the exception of intramucosal tumor curable with local therapy.
  • (2) Active infection requiring systemic therapy.
  • (3) Fever over 38 degrees Celsius
  • (4) Female during pregnancy, within 28 days of postparturition, or during lactation. Male who wants partner's pregnancy.
  • (5) Psychological disorder difficult to participate in this clinical study.
  • (6) Receiving continuous systemic corticosteroid or immunosuppressant treatment.
  • (7) Uncontrollable diabetes mellitus.
  • (8) History of unstable angina pectoris within three weeks or myocardial infarction within six months before registration. Uncontrolled valvular disease, dilated cardiomyopathy, and hypertrophic cardiomyopathy.
  • (9) Interstitial pneumonia or pulmonary fibrosis diagnosed by CT.
  • (10) Positive for HBs antigen.

研究者

发起方
IHO Seiji

相似试验